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BACKGROUND: Coronary artery disease (CAD) has been recognized as a serious and potentially life-threatening complication of 
Hepatitis C Virus (HCV) infection. High on-treatment platelet reactivity has been associated with high risk of ischemic events 
in patients with CAD, but data regarding the association with HCV infection are still lacking. This post hoc analysis aims to as-
sess high on-treatment platelet reactivity, severity of CAD, and long-term outcomes of patients with acute coronary syndrome 
(ACS) who were infected with HCV.
METHODS AND RESULTS: Patients with ACS who were infected with HCV (n=47) were matched to patients with ACS and without 
HCV (n=137) for age, sex, diabetes mellitus, hypertension, and renal function. HCV-infected patients with ACS had higher lev-
els of platelet reactivity (ADP10–light transmittance aggregometry, 56±18% versus 44±22% [P=0.002]; arachidonic acid–light 
transmittance aggregometry, 25±21% versus 16±15% [P=0.011]) and higher rates of high on-treatment platelet reactivity on 
clopidogrel and aspirin compared with patients without HCV. Moreover, HCV-infected patients with ACS had higher rates of 
multivessel disease (53% versus 30%; P=0.004) and 3-vessel disease (32% versus 7%; P<0.001) compared with patients 
without HCV. At long-term follow-up, estimated rates of major adverse cardiovascular events (cardiac death, nonfatal myo-
cardial infarction, and ischemia-driven revascularization) were 57% versus 34% (P=0.005) in HCV- and non–HCV-infected 
patients with ACS, respectively. In addition, thrombolysis In Myocardial Infarction (TIMI) major bleeding rates were higher in 
HCV-infected patients (11% versus 3%; P=0.043) compared with noninfected patients. Multivariable analysis demonstrated 
that HCV infection was an independent predictor of high on-treatment platelet reactivity, severity of CAD, and long-term 
outcome.
CONCLUSIONS: In this hypothesis-generating study, patients with ACS and HCV infection showed increased on-treatment plate-
let reactivity, more severe CAD, and worse prognosis compared with patients without HCV.
Key Words: acute coronary syndrome ■ hepatitis C virus ■ high on-treatment platelet reactivity ■ long-term outcome  
■ multivessel disease
Hepatitis C Virus (HCV) infection is endemic world-wide and a major health problem. Recent esti-mates showed an increase in its seroprevalence 
over the past decade to nearly 3%, corresponding to 
>185 million infected people worldwide.1 The virus exerts 
its action mainly on the liver, with serious, well-known, 
organ-related complications such as hepatic fibrosis, 
cirrhosis, and liver cancer. However, numerous extra-
hepatic manifestations may occur and frequently affect 
morbidity and mortality of infected patients.2 Among 
these, cardiovascular disease, including coronary ar-
tery disease (CAD), has been recognized as a serious 
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and potentially life-threatening complication of HCV 
infection. The pathogenic relationships between HCV 
infection, chronic liver disease, and atherosclerosis are 
still not completely elucidated. It has been hypothesized 
that HCV promotes atherogenesis and its complica-
tions through several direct and indirect mechanisms, 
including virus colonization and replication within the 
arterial wall,3 fatty liver disease and fibrosis, cryoglob-
ulinemia, oxidative stress, and enhanced production of 
inflammatory cytokines.4,5 Previous studies suggested 
the association between HCV infection and increased 
risk of carotid artery plaques and carotid intima–media 
thickening independent of other classic risk factors for 
atherosclerosis6,7 and with a possible local direct role 
of the virus in initiating the plaque.3 The observation 
that the virus induces production of proatherogenic 
cytokines5 and the link between chronic HCV infection 
and plaque development, growth, and instability sup-
port a role for HCV in the development of cerebrovas-
cular disease.
We hypothesized that a potential mechanism for 
the increased risk of recurrent acute coronary events 
could be high on-treatment platelet reactivity (HTPR) 
in patients with HCV. HTPR was shown to be an in-
dependent risk factor of major adverse cardiovascular 
events (MACE) after percutaneous coronary interven-
tion or acute coronary syndrome (ACS).8
The aim of the study was to assess platelet reactiv-
ity on dual antiplatelet therapy (DAPT), severity of CAD, 




The data that support the findings of this study are 
available from the corresponding author on rea-
sonable request. This study is based on a post-
hoc analysis of the Responsiveness to Clopidogrel 
and Stent-related Events (RECLOSE) 2-ACS study. 
The RECLOSE 2-ACS study was a prospective 
single-center cohort study of consecutive pa-
tients with ACS undergoing an invasive strategy, in 
whom platelet reactivity after clopidogrel loading 
was assessed.9 All interventions were performed 
according to current standards, and the type of 
stent implanted and the use of glycoprotein IIb/IIIa 
inhibitors were at the discretion of the operators; 
patients treated by thrombolysis were excluded. 
All patients were treated with clopidogrel 600-mg 
loading dose, followed by a 75-mg daily dose on 
top of aspirin. Platelet reactivity after clopidogrel 
loading was prospectively assessed by light trans-
mittance aggregometry (LTA) before hospital dis-
charge. For patients receiving both the loading 
dose of clopidogrel and a glycoprotein IIb/IIIa in-
hibitor in the catheterization laboratory, blood sam-
ples were obtained after 7 days. HTPR on aspirin 
was defined as platelet aggregation by arachidonic 
acid 1 mmol/L ≥20% and HTPR on clopidogrel as 
platelet aggregation by ADP 10 µmol/L ≥70%. The 
local ethics committee approved the study, and all 
patients gave informed consent.
Study Population
Of 1789 patients enrolled in the RECLOSE 2-ACS 
study, 60 were excluded because they were lost to 
follow-up within 1 year (n=17) or had an indication for 
chronic anticoagulant therapy (n=43). The remaining 
1729 patients were included in this analysis. Overall, 47 
CLINICAL PERSPECTIVE
What Is New?
• Patients with acute coronary syndrome who are 
infected with Hepatitis C Virus have increased 
platelet reactivity and higher rates of high on-
treatment platelet reactivity on dual antiplatelet 
therapy, either to aspirin or to clopidogrel, com-
pared with patients with acute coronary syn-
drome who are not infected with hepatitis C.
• Despite poor response to antiplatelet agents, 
patients with hepatitis C are at increased risk 
of major bleeding events during dual antiplatelet 
therapy.
What Are the Clinical Implications?
• Given their high likelihood of high on-treatment 
platelet reactivity on clopidogrel and of recur-
rent events, patients with acute coronary syn-
drome and hepatitis C might benefit from more 
potent antiplatelet therapy.
• Concurrent increased bleeding risk requires 
strict and careful patient follow-up and dual 
antiplatelet therapy length that is as short as 
possible.
Nonstandard Abbreviations and Acronyms
ACS acute coronary syndrome
CAD coronary artery disease
DAPT dual antiplatelet therapy
HCV hepatitis C virus
HTPR high on-treatment platelet reactivity
LTA light transmittance aggregometry
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patients were infected with HCV. Virological diagnosis 
of HCV infection is based on assays detecting a spe-
cific antibody to HCV.10 Patients with coinfection with 
hepatitis B virus and HIV were excluded.
Patients with ACS with and without HCV infection 
were matched 1:3 based on age, sex, diabetes melli-
tus, renal function, dyslipidemia, and hypertension.
End Points
The primary study end point was the proportion 
of patients with HTPR. The secondary end points 
of this study were a composite of MACE (cardiac 
death, reinfarction, and ischemia-driven revascu-
larization) at long-term follow-up, TIMI major bleed-
ing, and severity of CAD. Individual components of 
the composite end point were other secondary end 
points. Cardiac death includes death resulting from 
myocardial infarction (MI), sudden cardiac death, 
death due to heart failure, and death due to cardiac 
procedures. Nonfatal MI was defined according to 
the current universal definition of MI.11 All revascu-
larization events were considered to be ischemia-
driven if one of the following conditions was met: 
(1) a positive functional study corresponding to the 
area served by the target lesion; (2) ischemic ECG 
changes at rest in a distribution consistent with the 
target vessel; (3) typical ischemic symptoms refer-
able to the target lesion; (4) intravascular ultrasound 
of the target lesion with a minimal lumen area of 
≤4 mm2 for nonleft main lesions or ≤6 mm2 for left 
main lesions; and (5) fractional flow reserve of the 
target lesion ≤0.80 or instantaneous wave-free ratio 
≤0.90.
Follow-Up
All patients had scheduled follow-up at 1, 6, and 
12 months from the ACS and annually thereafter. All 
other possible information gathered from hospital re-
admission charts or by referring physicians, relatives, 
or municipality vital registries was entered into the pro-
spective database.
Statistical Analysis
Discrete data are expressed as frequencies and con-
tinuous data as mean±SD or median and interquartile 
range, as appropriate. The χ2 test was used to com-
pare categorical variables. Survival curves were gen-
erated with the use of the Kaplan–Meier method, and 
the difference between groups was assessed by the 
log-rank test. To address concerns about the potential 
confounding variables to affect the prognostic perfor-
mance of the HCV infection, we performed multivari-
able analysis by binary logistic and Cox proportional 
hazards models. The variables that were significantly 
different between the study groups (including HCV as 
a categorical variable) and those that are known to af-
fect the severity of HTPR and the incidence of MACE 
were incorporated in the model. The proportional haz-
ards assumption was assessed and satisfied graphi-
cally by plotting log (−log) survival curves against log 
survival time for each predictor category and verifying 
whether curves were parallel. Model discrimination 
was assessed with the C statistic and goodness of 
fit with the Hosmer-Lemeshow test. Binary logistic re-
gression and Cox proportional hazards models were 
used to test interaction among covariates. Preliminary 
matching procedures were performed to obtain a co-
variate-balanced control group. Covariates included in 
the model are those known to affect platelet reactivity. 
A propensity score–matched analysis (3:1) was per-
formed because of the expected differences in base-
line characteristics between patients with and without 
HCV infection. We performed nearest neighborhood 
matching with Mahalanobis distance (0.25-SD dis-
tance tolerance caliper). Bias reduction was assessed 
by comparing the standardized difference for pro-
pensity score and the other covariates before and 
after matching between the 2 groups (a value <10% 
after matching indicates inconsequential imbalance). 
P<0.05 was considered significant. All tests were 
2-sided. Analyses were performed with the SPSS sta-
tistical package v21 (IBM Corp).
RESULTS
Patient Population Clinical and 
Angiographic Characteristics
Baseline clinical characteristics of the whole popula-
tion are summarized in Table 1. Proper characteristics 
of HCV-infected patients are summarized in Table S1. 
As shown in Table 1, after matching, HCV-infected pa-
tients with ACS were more likely to have a higher rate 
of non–ST-segment–elevation MI (72% versus 53% in 
HCV-positive and HCV-negative patients, respectively; 
P=0.017) and worse left ventricle ejection fraction. 
Furthermore, after matching, HCV-infected patients 
with ACS had a higher rates of multivessel coronary 
disease (53% versus 30% in HCV-positive and HCV-
negative patients, respectively; P=0.004) and 3-vessel 
coronary disease (32% versus 7% in HCV-positive and 
HCV-negative patients, respectively; P<0.001) (Table 1). 
By multivariate analysis, HCV infection was indepen-
dently associated with 3-vessel disease (odds ratio, 
4.1; 95% CI, 2.18–7.77; P<0.001) (Table 2) and remained 
significantly associated with HTPR after propensity 
score adjustment (C statistic=0.69, P<0.001; P=0.61 
for Hosmer-Lemeshow test). Furthermore, interactions 
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HCV and HTPR on DAPT
Results of the platelet function tests used to evaluate 
platelet reactivity on aspirin and clopidogrel are pre-
sented in Figure 1.
As summarized in Table 3, patients with ACS and HCV 
had significantly higher arachidonic acid–LTA (25±21% 
versus 16±15%; P=0.011) than patients without HCV 
(Figure  1A). Accordingly, HTPR in response to aspirin 
therapy was significantly more frequent in patients with 
versus without HCV (40% versus 18% in HCV-positive 
and HCV-negative patients, respectively; P=0.002). By 
multivariate analysis, HCV infection was independently 
associated with HTPR on aspirin (odds ratio, 2.6; 95% CI, 
1.41–4.80; P=0.002) (Table 4) and remained significantly 
associated with HTPR after propensity score adjust-
ment (C statistic=0.63, P=0.001; P=0.81 for Hosmer-
Lemeshow test). Furthermore, interactions between 
HCV and covariates were not statistically significant.
As with aspirin, patients with ACS and HCV had sig-
nificantly higher ADP10-LTA (56±18% versus 44±22%; 
P=0.002) than patients without HCV (Figure  1B); the 
prevalence of HTPR in response to P2Y12 platelet recep-
tor inhibitor was significantly higher in those with versus 
without HCV (32% and 14% in HCV-positive and HCV-
negative patients, respectively; P=0.006). By multivariate 
analysis, HCV infection was independently associated 
with HTPR on clopidogrel (odds ratio, 2.85; 95% CI, 1.49–
5.45; P=0.002) (Table 5) and remained significantly asso-
ciated with HTPR after propensity score adjustment (C 
Table 1. Baseline Characteristics of Study Patients
All HCV− (n=1682) Matched HCV− (n=137) HCV+ (n=47) P Value*
Age, y, mean±SD 69±11 69±11 71±11 0.767
Age >75 y 638 (38) 67 (49) 20 (43) 0.452
Male sex 1372 (81) 99 (75) 33 (70) 0.788
Obesity 288 (17) 18 (13) 7 (15) 0.762
Hypertension 979 (58) 108 (79) 36 (77) 0.748
Dyslipidemia 769 (45) 65 (47) 25 (53) 0.349
Diabetes mellitus 338 (20) 38 (28) 13 (28) 0.992
Renal failure 174 (10) 15 (11) 5 (11) 0.953
Previous MI 309 (18) 29 (21) 14 (30) 0.228
Previous PCI 257 (15) 21 (15) 12 (25) 0.116
LVEF, mean±SD 49±8 49±8 45±11 0.013
LVEF ≤40% 513 (30) 44 (32) 57 (20) <0.001
Type of ACS
STEMI 806 (48) 65 (47) 13 (28) 0.018
NSTEMI/UA 911 (54) 72 (53) 34 (72) 0.017
Treated vessel
LM 123 (7) 12 (9) 7 (15) 0.425
LAD 903 (53) 74 (54) 32 (68) 0.241
LCx 569 (33) 46 (34) 25 (53) 0.017
RCA 679 (40) 56 (41) 25 (53) 0.425
Multivessel disease 984 (58) 41 (30) 25 (53) 0.004
Three-vessel disease 470 (28) 10 (7) 15 (32) <0.001
No. of vessels, mean±SD 1.8±0.8 1.8±0.8 1.8±1.1 0.998
No. of stent used, mean±SD 1.8±1.2 1.8±1.2 2.1±1.1 0.485
ACS indicates acute coronary syndrome; HCV, Hepatitis C Virus; LAD, left anterior descending artery; LCx, left circumflex artery; LM, left main; LVEF, left 
ventricular ejection fraction; MI, myocardial infarction; NSTEMI, non–ST-segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; 
RCA, right coronary artery; STEMI, ST-segment–elevation myocardial Infarction; and UA, unstable angina.
*By HCV (positive) vs matched HCV (negative).
Table 2. Predictors of 3-Vessel Disease
HR 95% CI P Value
HCV 4.1 2.18–7.77 <0.001
Age >75 y 1.4 1.07–1.71 0.010
Hypertension 1.3 1.02–1.61 0.031
HTPR on clopidogrel … … …
Diabetes mellitus 1.7 1.28–2.16 <0.001
LVEF ≤40 1.6 1.27–2.00 <0.001
Male sex 1.5 1.10–1.96 0.009
CKD … … …
Previous MI 3.0 2.30–3.89 <0.001
CKD indicates chronic kidney disease; HCV, Hepatitis C Virus; HR, hazard 
ratio; HTPR, high on-treatment platelet reactivity; LVEF, left ventricular 
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statistic=0.72, P=0.001; P=0.71 for Hosmer-Lemeshow 
test). Furthermore, interactions between HCV and covari-
ates were not statistically significant.
HCV and MACE
Follow-up rate was 95%, and median follow-up length 
was 2.8 years (interquartile range, 2.3–3.7 years). The 
MACE rate was 57% versus 34% (P=0.005) in HCV-
infected and noninfected patients with ACS, respec-
tively. Rates of secondary end points are reported in 
Table 6, and estimated cumulative incidences of MACE 
are reported in Figure 2.
By multivariable analysis, HCV infection was 
independently associated with MACE (hazard ratio, 
3.1; 95% CI, 1.69–5.63; P<0.001) (Table  7) and 
remained significantly associated with this end point 
after the assessment of the predictive accuracy of the 
multivariable analysis with the C statistic and goodness 
of fit with the Hosmer-Lemeshow test (C statistic=0.63, 
P=0.005; P=0.89 for Hosmer-Lemeshow test). 
Furthermore, interactions between HCV and covariates 
were not statistically significant.
TIMI major bleeding rates were higher in HCV-
infected patients than non–HCV-infected patients 
(11% versus 3% in HCV-positive and HCV-negative 
patients, respectively; P=0.043). As expected, re-
gardless of infection status, patients with HTPR 
had higher incidence of MACE (60% versus 36% 
in patients with versus without HTPR, respectively; 
P=0.014).
DISCUSSION
The main findings of the study are as follows:
1. Patients with ACS who are infected with HCV 
have increased platelet reactivity and a higher 
rate of HTPR on DAPT, either to aspirin or to 
clopidogrel, compared with patients with ACS but 
without HCV.
2. Patients with ACS who are infected with HCV have 
more extensive CAD.
3. HCV infection was confirmed to be an independent 
predictor of MACE in patients with ACS.
Figure 1. Response to anti-platelet agents in Hepatitis C virus (HCV) and non HCV patients.
A, Platelet reactivity to arachidonic acid (AA). Scattered distribution of 1 mmol/L AA-induced platelet 
aggregation. B, Platelet reactivity to ADP. Scattered distribution of 10 µM ADP-induced platelet 
aggregation. Blue dots: Hepatitis C Virus (HCV)–positive group; green dots: HCV-negative matched group.
Table 3. Platelet Function of Study Patients
All HCV− (n=1682) Matched HCV− (n=137) HCV+ (n=47) P Value*
HTPR on aspirin 339 (20) 25 (18) 19 (40) 0.002
HTPR on clopidogrel 235 (14) 19 (14) 15 (32) 0.006
Dual resistance 145 (9) 11 (8) 11 (23) 0.015
ADP-LTA, mean±SD 44±21 44±22 56±18 0.002
AA-LTA, mean±SD 17±18 16±15 25±21 0.011
DAPT at 2 y 1029 (61) 80 (58) 14 (30) 0.001
AA indicates arachidonic acid; DAPT, dual antiplatelet therapy; HCV, Hepatitis C Virus; HTPR, high on-treatment platelet reactivity; and LTA, light transmittance 
aggregometry.
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4. Despite poor response to antiplatelet agents, pa-
tients with HCV are at increased risk of major bleed-
ing events during DAPT.
In this study, we assessed the impact of HCV infec-
tion on treatment residual platelet reactivity by match-
ing ACS patients with and without HCV to adjust for 
potential confounding factors. To our knowledge, for 
the first time, we were able to demonstrate that pa-
tients with ACS and HCV exhibit increased on-treat-
ment platelet reactivity when treated by aspirin but also 
by clopidogrel, compared with patients with ACS but 
without HCV.
The odds of patients with HTPR on clopidogrel 
were increased by almost 3-fold among those with 
HCV. All results above remained significant after con-
trol matching and adjustment for potential confound-
ing factors, clearly demonstrating the robustness and 
independence of HCV status as a predictor of HTPR.
Several pathophysiologic findings among HCV 
patients support our results. First, the virus itself is 
known to affect platelet activity though internaliza-
tion into platelets.12,13 In addition, inadequate hepatic 
conversion of clopidogrel to its active metabolite as 
a result of liver disease, the chronic inflammatory 
syndrome, and the higher rate of diabetes melli-
tus14 and insulin-resistance15 in HCV patients are 
concomitant factors that, negatively, increase plate-
let function. Furthermore, a multifactorial platelet 
count decrease (ie, thrombocytopenia) is frequently 
observed in cirrhotic patients, caused by numerous 
pathophysiologic modifications, such as decreased 
liver production of platelet growth factors and pe-
ripheral sequestration in hypersplenism due to portal 
hypertension.16
In our study, HCV infection was strongly associated 
with the severity of CAD, and this association per-
sisted after control matching and adjustment for po-
tential confounding factors. This result confirmed the 
pathophysiologic thesis in which the virus promotes 
atherosclerotic cardiovascular disease because of 
derangements in metabolic pathways and chronic in-
flammation.17 Furthermore, HCV-infected patients had 
a more complex clinical profile characterized by higher 
probability of non–ST-segment–elevation MI and left 
ventricular dysfunction.
Patients with ACS and HCV showed an increased 
risk of MACE, possibly as a consequence of HTPR 
on DAPT18 or of increased extension and severity of 
CAD, as well as more advanced left ventricular dys-
function. Therefore, we confirmed previous findings 
showing doubled all-cause mortality in HCV-positive 
versus HCV-negative patients.19 In infected patients, 
the reported increased mortality is both liver-related 
and non–liver-related, the latter being ascribed mainly 
to cardiovascular disease. Moreover, in our cohort 
of patients with ACS, HCV-infected patients showed 
higher risk of both ischemic events (mainly driven by 
nonfatal MI and revascularizations) and bleeding com-
plications. It is well known that the high bleeding risk 
in HCV-infected patients is caused by rebalanced he-
mostasis sustained by low production of both clotting 
factors, vitamin K deficiency, enhanced synthesis of 
fibrinolytic factors, or development of esophageal var-
ices and hypersplenism as consequences of portal 
hypertension.20
These findings have some clinical perspectives. 
First, given the high likelihood of HTPR on clopi-
dogrel and, at the same time, high recurrent event 
rates, patients with ACS and HCV might benefit 
from more potent antiplatelet therapy. However, 
concurrent increased bleeding risk requires strict 
and careful patient follow-up and DAPT length that 
is as short as possible. Second, viral eradication by 
use of increasingly effective antiviral drugs could be 
associated with an improvement in platelet function 
and a decrease in cardiovascular risk.21 However, 
new direct-acting antiviral agents for the treatment 
of HCV have numerous drug–drug interactions with 
platelet P2Y12 inhibitors; therefore, recommendations 
on the type and length of DAPT in patients with ACS 
and HCV infection should be made at the individ-
ual level after carefully balancing the ischemic and 
Table 4. Predictors of HTPR on Aspirin
HR 95% CI P Value
HCV 2.6 1.42–4.83 0.002
Age >75 1.8 1.44–2.37 <0.001
Hypertension … … …
Diabetes mellitus 1.6 1.20–2.09 0.001
LVEF ≤40% … … …
Smokers … … …
CKD … … …
CKD indicates chronic kidney disease; HCV, Hepatitis C Virus; HR, hazard 
ratio; HTPR, high on-treatment platelet reactivity; and LVEF, left ventricular 
ejection fraction.
Table 5. Predictors of HTPR on Clopidogrel
HR 95% CI P Value
HCV 2.8 1.49–5.44 0.002
Age >75 1.7 1.31–2.31 <0.001
Dyslipidemia 1.4 1.10–1.91 0.008
Diabetes mellitus 1.7 1.23–2.23 0.001
LVEF ≤40% … … …
Smokers … … …
CKD … … …
CKD indicates chronic kidney disease; HCV, Hepatitis C Virus; HR, hazard 
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bleeding risks and adequately considering concur-
rent therapies.
In conclusion, patients with ACS and HCV infection 
have increased on-treatment platelet reactivity, either 
to aspirin or to clopidogrel; more severe CAD; and in-
creased adverse clinical events than patients without 
HCV.
Our study must be evaluated in the light of some 
limitations. First, this is a nonrandomized single-center 
study. However, we used propensity score matching 
to make the patient groups comparable according to 
the measured confounders. Nevertheless, residual 
unmeasured confounding cannot be excluded. Wider 
studies and randomized trials are needed to validate 
the impact of HCV infection on platelet function and 
its prognostic role in patients with ACS. Second, be-
cause of the limited size of the HCV group, our study 
was not properly powered for hard clinical end points, 
and it should be considered only as explorative and 
hypothesis generating. Third, our patients did not re-
ceive the 2 new P2Y12 inhibitors (ie, prasugrel and tica-
grelor), which were not available at the time of study 
enrollment. Consequently, we are not able to spec-
ulate about the extent to which these results would 
be different using the new drugs rather than clopido-
grel. Therefore, our results cannot be generalized to 
patients receiving prasugrel or ticagrelor. However, 
because of the perceived high bleeding risk and po-
tential drug–drug interactions with the newer anti-
platelet agents, patients with HCV frequently receive 
clopidogrel in association with aspirin. Fourth, platelet 
reactivity was assessed only by LTA. However, LTA is 
the most well-established laboratory method for the 
determination of HTPR,22 and its results have been 
strongly associated with an increased incidence of 
MACE.8 Fifth, we are not able to analyze the influence 
of the different HCV genotypes, viral load, and severity 
of liver disease because of the relatively small size of 
the HCV-infected group. Finally, HTPR was defined as 
an ADP10–LTA test >70%, based on the RECLOSE-1 
result,23 although not corresponding to the current 
standard. Nevertheless, at the time of study planning, 
the prognostic value of point-of-care assays was still 
to be defined.24
Table 6. Outcomes of Study Population
All Cohort HCV− (n=1682) Matched HCV− (n=137) HCV+ (n=47) P Value*
MACE 539 (32) 47 (34) 27 (57) 0.005
Cardiovascular death 113 (7) 11 (8) 2 (4) 0.384
Nonfatal MI 43 (3) 4 (3) 15 (32) <0.001
Ischemia-driven revascularization 445 (26) 37 (27) 20 (42) 0.047
Stent thrombosis 51 (3) 4 (3) 2 (4) 0.631
TIMI major bleeding 37 (2) 4 (3) 5 (11) 0.043
HCV indicates Hepatitis C Virus; MACE, major adverse cardiovascular events; MI, myocardial infarction; and TIMI, thrombolysis in myocardial infarction.
*By log-rank test.
Figure 2. Major adverse cardiovascular events (MACE) 
cumulative incidence curves at 24-month follow-up.
Green curve: Hepatitis C Virus (HCV)–infected patients. Blue 
curve: HCV-negative matched patients. MACE, a composite end 
point of cardiovascular death, nonfatal myocardial infarction, and 
ischemia-driven revascularization.
Table 7. Predictors of MACE
HR 95% CI P Value
HCV 3.1 1.69–5.63 <0.001
Age >75 y … … …
Hypertension … … …
HTPR on clopidogrel … … …
Multivessel disease 2.2 1.74–2.70 <0.001
Diabetes mellitus … … …
LVEF ≤40 … … …
Male sex … … …
CKD … … …
CKD indicates chronic kidney disease; HCV, Hepatitis C Virus; HR, hazard 
ratio; HTPR, high on-treatment platelet reactivity; LVEF, left ventricular 
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Table S1. Proper characteristics of HCV-infected patients. 
 
 HCV + pts 
 (n= 47) 
Duration of HCV infection, 
years, mean SD 
19 (7) 
Cirrhosis, % 4 (8) 
Serum Albumin, g/L, mean 
SD 
(n.v. 35-50 g/L)  
48 (10) 
Serum Ferritin, ng/dL, 
mean SD 
(n.v. 20-200 mg/dL) 
155 (122) 
Total Bilirubin, mg/dL, 
mean SD 
(n.v. 0.2-1.0 mg/dL) 
0.72 (0.29)  
Total Cholesterol, mg/dL, 
mean SD  
(n.v. 130-200 mg/dL) 
153 (40) 
Platelet count, x 10^9/L, 
mean SD 
(n.v. 140 – 440  x 10^9/L) 
205 (97) 
Prothrombin time, sec, 
mean SD 
(n.v 22-38 sec) 
31 (4) 
AST, U/L, mean SD 









ALT, U/L, mean SD 
(n.v. 12-65 U/L) 
44 (29) 
GGT, U/L, mean SD 
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